Previous 10 | Next 10 |
Disney (DIS) took another step down in Friday's midday action, as leadership drama at the entertainment giant propelled the latest retreat in a downtrend that has marked most of June so far. Meanwhile, Illumina (NASDAQ:ILMN) also lost ground on management uncertainty, with the stock dropping ...
Gainers: Cogent Biosciences (COGT) +89%. Redbox Entertainment (RDBX) +48%. Alpha Tau Medical (DRTS) +23%. Bright Green Corporation (BGXX) +17%. Aridis Pharmaceuticals (ARDS) +18%. Wah Fu Education Group (WAFU) +14%. Powerbridge Technologies (PBTS) +12%. Hycroft Mining Holding Corporation (HYM...
Fulcrum Therapeutics (NASDAQ:FULC) dropped ~48% in the morning hours Friday after the clinical-stage pharma shared proof-of-concept data from an ongoing Phase 1b trial for oral experimental therapy FTX-6058 in sickle cell disease (SCD). The first cohort of the study had enrolled six...
Gainers: Cogent Biosciences (COGT) +56%. IO Biotech (IOBT) +9%. Celularity (CELU) +6%. PolarityTE (PTE) +6%. Aridis Pharmaceuticals (ARDS) +5%. Losers: Fulcrum Therapeutics (FULC) -48%. Caribou Biosciences (CRBU) -33%. DBV Technologies (DBVT) -18%. Card...
Paltalk PALT +38% on $2.7M acquisition of ManyCam assets. TuSimple Holdings (TSP) +10% launches hydron, producing hydrogen-powered autonomous-ready, freight trucks. Porch Group (PRCH) +8%. HeartCore (HTCR) +8%. Bilibili (BILI) +8%. Rent the Runway RENT +8% on Q1 resul...
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel oral HbF inducer - FTX-6058 was generally well tolerated; no serious treatment emerg...
Fulcrum Therapeutics (NASDAQ:FULC) is trading higher on Tuesday after the clinical-stage company announced that Acceleron Pharma Inc., a recent acquisition of Merck (MRK), ended an agreement for drug candidates targeted at lung diseases. Per the 2019 collaboration and license agreement, Fulcr...
- FTX-6058 is the only oral hemoglobin F (HbF) inducer in clinical development -Data will include initial HbF changes, safety, tolerability, pharmacokinetics, and other pharmacodynamic measures from the ongoing 6 mg dose cohort of FTX-6058 in adults with sickle cell disease ...
Fulcrum Therapeutics, Inc. (FULC) Q1 2022 Earnings Conference Call May 9, 2022, 8:00 am ET Company Participants Naomi Aoki - SVP, Corporate Communications & IR Bryan Stuart - President & CEO Judy Dunn - President, R&D Esther Rajavelu - CFO Chris Morabito - CMO Paul Bruno - Executi...
Fulcrum Therapeutics press release (NASDAQ:FULC): Q1 GAAP EPS of -$0.64 misses by $0.02. Revenue of $2.6M (-45.7% Y/Y) misses by $1.34M. As of March 31, 2022, cash, cash equivalents, and marketable securities were $195.1 million, as compared to $218.2 million as of December 31, 2021...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...